Nucleic acid detection with CRISPR-Cas13a/C2c2

Jonathan S. Gootenberg(Broad Institute), Omar O. Abudayyeh(Broad Institute), Jeong Wook Lee(Harvard University), Patrick Essletzbichler(Broad Institute), Aaron J. Dy(Broad Institute), Julia Joung(Broad Institute), Vanessa K. Verdine(Broad Institute), Nina M. Donghia(Harvard University), Nichole M. Daringer(Massachusetts Institute of Technology), Catherine A. Freije(Broad Institute), Cameron Myhrvold(Broad Institute), Roby P. Bhattacharyya(Broad Institute), Jonathan Livny(Broad Institute), Aviv Regev(Broad Institute), Eugene V. Koonin(National Institutes of Health), Deborah T. Hung(Broad Institute), Pardis C. Sabeti(Broad Institute), James J. Collins(Broad Institute), Feng Zhang(Broad Institute)
Science
April 13, 2017
Cited by 3,776Open Access
Full Text

Abstract

Rapid, inexpensive, and sensitive nucleic acid detection may aid point-of-care pathogen detection, genotyping, and disease monitoring. The RNA-guided, RNA-targeting clustered regularly interspaced short palindromic repeats (CRISPR) effector Cas13a (previously known as C2c2) exhibits a "collateral effect" of promiscuous ribonuclease activity upon target recognition. We combine the collateral effect of Cas13a with isothermal amplification to establish a CRISPR-based diagnostic (CRISPR-Dx), providing rapid DNA or RNA detection with attomolar sensitivity and single-base mismatch specificity. We use this Cas13a-based molecular detection platform, termed Specific High-Sensitivity Enzymatic Reporter UnLOCKing (SHERLOCK), to detect specific strains of Zika and Dengue virus, distinguish pathogenic bacteria, genotype human DNA, and identify mutations in cell-free tumor DNA. Furthermore, SHERLOCK reaction reagents can be lyophilized for cold-chain independence and long-term storage and be readily reconstituted on paper for field applications.


Related Papers

No related papers found

Powered by citation graph analysis